TAKEDA PHARMA (TKD HM) stock market data APIs
€31.9166
-0.3(-0.9%)
as of March 17, 2026
Try our APIs with
free plan!
TAKEDA PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.HM.
Prev. Close
31.9166
Open
31.6198
High
31.9774
Low
31.4928
52 wk Range
23.11-31.9
Market Cap
37 823 M
Dividends (Yield)
3.2068
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA data using free add-ons & libraries
Get TAKEDA PHARMA Fundamental Data
TAKEDA PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA News
New
KROS: Is the Discount Book Value a Value Trap?
Keros Therapeutics KROS posted a dramatic revenue jump in 2025, but the mix matters as much as the magnitude. The shares also trade at a steep discount to book value, creating the classic biotech ques...
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros Therapeutics KROS enters 2026 with a clearer catalyst stack and a tighter operational focus. The near-term setup is led by rinvatercept, with study starts and regulatory interactions now mapped ...
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Recent returns and business profile Takeda Pharmaceutica...
Rixubis (Takeda Pharmaceutical) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Company Logo Key market opportunities include the expansion of personalized hemophilia management, growth in home infusion services, increased R&D funding, and the rising incidence of hemophilia. Fur...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
